An Open, Multicenter Phase II Clinical Study to Evaluate Safety and Efficacy of HLX208 (BRAF V600E Inhibitor) Combined With Cetuximab in Patients With Metastatic Colorectal Cancer (mCRC)
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Cetuximab (Primary) ; RX 208 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 16 Aug 2023 Planned End Date changed from 15 Aug 2023 to 15 Jan 2025.
- 16 Aug 2023 Planned primary completion date changed from 15 Aug 2022 to 15 Jun 2024.
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.